脊髄性筋萎縮症の世界市場レポート 2025年

脊髄性筋萎縮症市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.2％で65億9,000万米ドルに成長します。予測期間中、認知度と診断の向上、治療へのアクセス拡大、希少疾患に対するヘルスケア投資の増加、良好な規制環境、医療費の増加などにより成長が見込まれます。この期間の主な動向としては、経口療法の発展、遺伝子治療の採用、ドラッグデリバリーシステムの技術革新、SMA治療開発における人工知能の統合、遺伝子編集技術の利用などが挙げられます。

希少遺伝性疾患の有病率の増加は、脊髄性筋萎縮症（SMA）市場の成長を促進すると予想されます。遺伝子の変異によって引き起こされる希少遺伝性疾患は、人口のごく一部に影響を及ぼし、しばしば深刻で慢性的な健康問題につながります。このような希少遺伝性疾患の増加は、診断技術の進歩、認知度の向上、遺伝子検査へのアクセスの改善が、より多くの症例の特定と報告をもたらしたことに起因しています。希少遺伝性疾患である脊髄性筋萎縮症は、遺伝性疾患の理解に伴う課題と機会の一例であり、遺伝性疾患における継続的研究の必要性を浮き彫りにしています。例えば、2023年7月、英国の国家統計局は、SMN1の遺伝子検査により、より正確な疫学調査が可能になり、SMAは1万人から2万人に1人の割合で発生し、罹患患者の95％以上がホモ接合性のSMN1欠失を有すると報告しました。その結果、希少遺伝性疾患の有病率の上昇がSMA市場の成長を促進すると予想されています。

脊髄性筋萎縮症市場の各社は、特に小児患者や嚥下困難な患者向けに、服薬アドヒアランスと服薬のしやすさを向上させる革新的な治療法を開発しています。そのような革新的な治療法のひとつがドライシロップで、粉末状の薬剤を水で再構成してから使用するもので、錠剤やカプセルを飲み込むのに苦労する小児や患者に処方されることが多いです。例えば、2024年9月、日本の製薬会社である中外製薬株式会社は、厚生労働省からエブリスディ（リスディプラム）の適応拡大承認を取得しました。今回の承認により、前症候性SMAへの使用が認められ、生後2ヶ月未満の乳児への投与が拡大されました。この承認は、症状発現前の治療が可能となり、患児の治療成績が改善する可能性があることから、重要なマイルストーンとなります。この決定は、SMAと診断されたがまだ症状の出ていない乳児における本剤の安全性と有効性を評価したRAINBOWFISH試験のデータによって裏付けられました。その結果、治療を受けた乳幼児は12ヶ月までに、支えのない座位や運動能力の向上といった発達のマイルストーンに達したことが示され、早期に投与することで病気の進行を変える可能性があることが実証されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界脊髄性筋萎縮症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の脊髄性筋萎縮症市場：成長率分析
• 世界の脊髄性筋萎縮症市場の実績：規模と成長, 2019-2024
• 世界の脊髄性筋萎縮症市場の予測：規模と成長, 2024-2029, 2034F
• 世界脊髄性筋萎縮症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脊髄性筋萎縮症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプ1（重症）
• タイプ2（中級）
• タイプ3（軽度）
• タイプ4（成人）
• 世界の脊髄性筋萎縮症市場年齢別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 大人
• 世界の脊髄性筋萎縮症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物療法
• 遺伝子治療
• 世界の脊髄性筋萎縮症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の脊髄性筋萎縮症市場、タイプ1（重症）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳児発症型SMA
• 重度進行性SMA
• 世界の脊髄性筋萎縮症市場、タイプ2（中程度）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 早期発症型SMA
• 非進行性SMA
• 世界の脊髄性筋萎縮症市場、タイプ3（軽度）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 若年性SMA
• 軽度進行性SMA
• 世界の脊髄性筋萎縮症市場タイプ4（成人）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人発症型SMA
• 晩発性SMA

第7章 地域別・国別分析

• 世界の脊髄性筋萎縮症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の脊髄性筋萎縮症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脊髄性筋萎縮症市場：競合情勢
• 脊髄性筋萎縮症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Chugai Pharmaceutical Co. Ltd.
• Genentech Inc.
• PTC Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• Biohaven Ltd.
• Catalyst Pharmaceuticals Inc.
• RegenXBio Inc.
• Cytokinetics Inc.
• AveXis Inc.
• Scholar Rock Inc.
• Genethon
• CANbridge Pharmaceuticals Inc.
• NMD Pharma A/S
• Hanugen Therapeutics Inc.
• Beijing Jinlan Gene Technology Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 脊髄性筋萎縮症市場2029：新たな機会を提供する国
• 脊髄性筋萎縮症市場2029：新たな機会を提供するセグメント
• 脊髄性筋萎縮症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder marked by the progressive degeneration of motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, which results in a deficiency of survival motor neuron (SMN) protein. SMA primarily impacts voluntary muscle movements, particularly those necessary for walking, swallowing, and breathing.

SMA is categorized into four main types, type 1 (severe), type 2 (intermediate), type 3 (mild), and type 4 (adult). Type 1, or severe SMA, is the most critical form, characterized by profound muscle weakness and an inability to sit or move independently, often leading to death before the age of 2 without treatment. The condition affects both pediatric and adult patients. Treatment options include drug therapy and gene therapy, which are available through various end users, including hospital pharmacies, online pharmacies, and retail pharmacies.

The spinal muscular atrophy market research report is one of a series of new reports from The Business Research Company that provides spinal muscular atrophy market statistics, including the spinal muscular atrophy industry global market size, regional shares, competitors with the spinal muscular atrophy market share, detailed spinal muscular atrophy market segments, market trends, and opportunities, and any further data you may need to thrive in the spinal muscular atrophy industry. This spinal muscular atrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The spinal muscular atrophy market size has grown rapidly in recent years. It will grow from $3.53 billion in 2024 to $4.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth during the historic period can be attributed to factors such as improved diagnosis and early detection, the rising prevalence of rare genetic diseases, enhanced healthcare infrastructure, government and regulatory support, and a growing demand for addressing unmet healthcare needs.

The spinal muscular atrophy market size is expected to see rapid growth in the next few years. It will grow to $6.59 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. For the forecast period, growth is expected due to increased awareness and diagnosis, expanded access to treatments, higher healthcare investments in rare diseases, a favorable regulatory environment, and increased healthcare expenditure. Key trends during this period include advancements in oral therapies, the adoption of gene therapy, technological innovations in drug delivery systems, the integration of artificial intelligence in SMA treatment development, and the use of gene editing technologies.

The increasing prevalence of rare genetic diseases is expected to drive the growth of the spinal muscular atrophy (SMA) market. Rare genetic disorders, caused by mutations in genes, affect a small segment of the population and often lead to severe, chronic health issues. This rise in rare genetic diseases can be attributed to advancements in diagnostic technologies, greater awareness, and improved access to genetic testing, which have resulted in the identification and reporting of more cases. Spinal muscular atrophy, a rare genetic disorder, serves as an example of the challenges and opportunities associated with understanding inherited diseases, highlighting the need for ongoing research in genetic conditions. For example, in July 2023, the Office for National Statistics in the UK reported that genetic testing of SMN1 has enabled more precise epidemiological studies, showing that SMA occurs in 1 in 10,000 to 20,000 live births and that over 95% of affected patients have homozygous SMN1 deletion. As a result, the rising prevalence of rare genetic diseases is expected to drive the growth of the SMA market.

Companies in the spinal muscular atrophy market are developing innovative treatments to improve medication adherence and ease of administration, particularly for pediatric patients and those with difficulty swallowing. One such innovation is dry syrup, a powdered medication that is reconstituted with water before use, often prescribed for children and patients who struggle to swallow pills or capsules. For instance, in September 2024, Chugai Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, received regulatory approval from Japan's Ministry of Health, Labour and Welfare for an expanded indication of its drug Evrysdi (risdiplam). This approval allows the drug's use in pre-symptomatic SMA and extends its dosage to infants under two months old. This approval is a significant milestone, as it allows treatment before the onset of symptoms, potentially improving therapeutic outcomes for affected infants. The decision was supported by data from the RAINBOWFISH study, which assessed the drug's safety and efficacy in infants diagnosed with SMA but not yet symptomatic. Results showed that treated infants reached developmental milestones, such as unsupported sitting and improved motor skills, by 12 months, demonstrating the drug's potential to alter the disease's progression when administered early.

In January 2024, Voyager Therapeutics, a US-based biotechnology company, entered into a partnership with Novartis AG to advance gene therapies for Huntington's disease and spinal muscular atrophy. The collaboration utilizes Voyager's proprietary TRACER capsids and advanced technology, while Novartis, a Swiss pharmaceutical company, brings its expertise in developing drugs and eye care products.

Major players in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Biohaven Ltd., Catalyst Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., and Beijing Jinlan Gene Technology Co. Ltd.

North America was the largest region in the spinal muscular atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spinal muscular atrophy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the spinal muscular atrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The spinal muscular atrophy market consists of revenues earned by entities by providing services such as gene delivery services, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The spinal muscular atrophy market also includes sales of therapy products, diagnostic kits, medical devices, and nutritional products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Spinal Muscular Atrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on spinal muscular atrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for spinal muscular atrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The spinal muscular atrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1 (Severe); Type 2 (Intermediate); Type 3 (Mild); Type 4 (Adult)
• 2) By Age: Pediatric; Adults
• 3) By Treatment: Drug Therapy; Gene Therapy
• 4) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy
• Subsegments:
• 1) By Type 1 (Severe): Infantile-Onset SMA; Severe Progressive SMA
• 2) By Type 2 (Intermediate): Early-Onset SMA; Non-progressive SMA
• 3) By Type 3 (Mild): Juvenile-Onset SMA; Mild Progressive SMA
• 4) By Type 4 (Adult): Adult-Onset SMA; Late-Onset SMA
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Novartis AG; Biogen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Spinal Muscular Atrophy Market Characteristics

3. Spinal Muscular Atrophy Market Trends And Strategies

4. Spinal Muscular Atrophy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Spinal Muscular Atrophy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Spinal Muscular Atrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Spinal Muscular Atrophy Market Growth Rate Analysis
• 5.4. Global Spinal Muscular Atrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Spinal Muscular Atrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Spinal Muscular Atrophy Total Addressable Market (TAM)

6. Spinal Muscular Atrophy Market Segmentation

• 6.1. Global Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 (Severe)
• Type 2 (Intermediate)
• Type 3 (Mild)
• Type 4 (Adult)
• 6.2. Global Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adults
• 6.3. Global Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Therapy
• Gene Therapy
• 6.4. Global Spinal Muscular Atrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital pharmacy
• Online pharmacy
• Retail pharmacy
• 6.5. Global Spinal Muscular Atrophy Market, Sub-Segmentation Of Type 1 (Severe), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infantile-Onset SMA
• Severe Progressive SMA
• 6.6. Global Spinal Muscular Atrophy Market, Sub-Segmentation Of Type 2 (Intermediate), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-Onset SMA
• Non-progressive SMA
• 6.7. Global Spinal Muscular Atrophy Market, Sub-Segmentation Of Type 3 (Mild), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Juvenile-Onset SMA
• Mild Progressive SMA
• 6.8. Global Spinal Muscular Atrophy Market, Sub-Segmentation Of Type 4 (Adult), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult-Onset SMA
• Late-Onset SMA

7. Spinal Muscular Atrophy Market Regional And Country Analysis

• 7.1. Global Spinal Muscular Atrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Spinal Muscular Atrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Spinal Muscular Atrophy Market

• 8.1. Asia-Pacific Spinal Muscular Atrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Spinal Muscular Atrophy Market

• 9.1. China Spinal Muscular Atrophy Market Overview
• 9.2. China Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Spinal Muscular Atrophy Market

• 10.1. India Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Spinal Muscular Atrophy Market

• 11.1. Japan Spinal Muscular Atrophy Market Overview
• 11.2. Japan Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Spinal Muscular Atrophy Market

• 12.1. Australia Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Spinal Muscular Atrophy Market

• 13.1. Indonesia Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Spinal Muscular Atrophy Market

• 14.1. South Korea Spinal Muscular Atrophy Market Overview
• 14.2. South Korea Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Spinal Muscular Atrophy Market

• 15.1. Western Europe Spinal Muscular Atrophy Market Overview
• 15.2. Western Europe Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Spinal Muscular Atrophy Market

• 16.1. UK Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Spinal Muscular Atrophy Market

• 17.1. Germany Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Spinal Muscular Atrophy Market

• 18.1. France Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Spinal Muscular Atrophy Market

• 19.1. Italy Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Spinal Muscular Atrophy Market

• 20.1. Spain Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Spinal Muscular Atrophy Market

• 21.1. Eastern Europe Spinal Muscular Atrophy Market Overview
• 21.2. Eastern Europe Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Spinal Muscular Atrophy Market

• 22.1. Russia Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Spinal Muscular Atrophy Market

• 23.1. North America Spinal Muscular Atrophy Market Overview
• 23.2. North America Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Spinal Muscular Atrophy Market

• 24.1. USA Spinal Muscular Atrophy Market Overview
• 24.2. USA Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Spinal Muscular Atrophy Market

• 25.1. Canada Spinal Muscular Atrophy Market Overview
• 25.2. Canada Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Spinal Muscular Atrophy Market

• 26.1. South America Spinal Muscular Atrophy Market Overview
• 26.2. South America Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Spinal Muscular Atrophy Market

• 27.1. Brazil Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Spinal Muscular Atrophy Market

• 28.1. Middle East Spinal Muscular Atrophy Market Overview
• 28.2. Middle East Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Spinal Muscular Atrophy Market

• 29.1. Africa Spinal Muscular Atrophy Market Overview
• 29.2. Africa Spinal Muscular Atrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Spinal Muscular Atrophy Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Spinal Muscular Atrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Spinal Muscular Atrophy Market Competitive Landscape And Company Profiles

• 30.1. Spinal Muscular Atrophy Market Competitive Landscape
• 30.2. Spinal Muscular Atrophy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Spinal Muscular Atrophy Market Other Major And Innovative Companies

• 31.1. Chugai Pharmaceutical Co. Ltd.
• 31.2. Genentech Inc.
• 31.3. PTC Therapeutics Inc.
• 31.4. Ionis Pharmaceuticals Inc.
• 31.5. Biohaven Ltd.
• 31.6. Catalyst Pharmaceuticals Inc.
• 31.7. RegenXBio Inc.
• 31.8. Cytokinetics Inc.
• 31.9. AveXis Inc.
• 31.10. Scholar Rock Inc.
• 31.11. Genethon
• 31.12. CANbridge Pharmaceuticals Inc.
• 31.13. NMD Pharma A/S
• 31.14. Hanugen Therapeutics Inc.
• 31.15. Beijing Jinlan Gene Technology Co. Ltd.

32. Global Spinal Muscular Atrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Spinal Muscular Atrophy Market

34. Recent Developments In The Spinal Muscular Atrophy Market

35. Spinal Muscular Atrophy Market High Potential Countries, Segments and Strategies

• 35.1 Spinal Muscular Atrophy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Spinal Muscular Atrophy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Spinal Muscular Atrophy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer